The AndroCoV Clinical Scoring for COVID-19 Diagnosis: A Prompt, Feasible, Costless, and Highly Sensitive Diagnostic Tool Based on a 1757-Patient Cohort

January 2021 in “ Cureus ”

Flavio Cadegiani, Ricardo Ariel Zimerman, Bruno Campello de Souza, John McCoy, Rute Alves Pereira e Costa, Carlos Gustavo Wambier, Andy Goren

Studysummary This study suggests that the AndroCoV clinical scoring system may be a more sensitive and cost-effective tool for diagnosing COVID-19 compared to RT-PCR-SARS-CoV-2 tests, potentially reducing diagnostic delays and false negatives.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on assets.cureus.com →

Discuss this study in the Community →

Research cited in this study

12 / 12 results

The AndroCoV Clinical Scoring for COVID-19 Diagnosis: A Prompt, Feasible, Costless, and Highly Sensitive Diagnostic Tool Based on a 1757-Patient Cohort

research The AndroCoV Clinical Scoring for COVID-19 Diagnosis: A Prompt, Feasible, Costless, and Highly Sensitive Diagnostic Tool Based on a 1757-Patient Cohort

14 citations , January 2021 in “Cureus”

This study suggests that the AndroCoV clinical scoring system may be a more sensitive and cost-effective tool for diagnosing COVID-19 compared to RT-PCR-SARS-CoV-2 tests, potentially reducing diagnostic delays and false negatives.

Clinical Diagnosis of COVID-19: A Prompt, Feasible, Costless, and Highly Sensitive Diagnostic Tool Based on a 1,757-Patient Cohort (The AndroCoV Clinical Scoring for COVID-19 Diagnosis)

research Clinical Diagnosis of COVID-19: A Prompt, Feasible, Costless, and Highly Sensitive Diagnostic Tool Based on a 1,757-Patient Cohort (The AndroCoV Clinical Scoring for COVID-19 Diagnosis)

1 citations , January 2021 in “Research Square (Research Square)”

This study found that the AndroCoV Clinical Scoring for COVID-19 Diagnosis may offer a more sensitive and timely diagnostic tool for COVID-19 than conventional rtPCR testing, especially enhancing potential treatment timing.

research COVID-19, Androgens, and Androgenic Alopecia

6 citations , December 2020 in “Dermatological reviews”

This review discusses the potential link between androgenic alopecia, androgens, and the severity of COVID-19, highlighting possible therapeutic targets but reports no new clinical results.

Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide, Ivermectin, or Hydroxychloroquine in Outpatient Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated Patients

research Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide, Ivermectin, or Hydroxychloroquine in Outpatient Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated Patients

11 citations , November 2020 in “bioRxiv (Cold Spring Harbor Laboratory)”

This study observed that early treatment with azithromycin and either nitazoxanide, ivermectin, or hydroxychloroquine in COVID-19 patients may reduce viral shedding, symptom duration, and respiratory complications compared to untreated patients.

Hydroxychloroquine, Nitazoxanide, and Ivermectin Have Similar Effects in Early COVID-19: A Head-to-Head Comparison of the Pre-AndroCoV Trial

research Hydroxychloroquine, Nitazoxanide, and Ivermectin Have Similar Effects in Early COVID-19: A Head-to-Head Comparison of the Pre-AndroCoV Trial

4 citations , October 2020 in “Research Square (Research Square)”

In this study, hydroxychloroquine, nitazoxanide, and ivermectin demonstrated similar efficacy for overall clinical outcomes in COVID-19 when administered early with azithromycin, vitamins, and supplements, with nitazoxanide showing the strongest antiviral activity and safety profile among the three.

research Clinical Symptoms of Hyperandrogenic Women Diagnosed with COVID-19

29 citations , October 2020 in “Journal of the European Academy of Dermatology and Venereology”

This article is a discussion piece that examines the clinical symptoms of hyperandrogenic women with COVID-19, without reporting new research findings.

Azithromycin With Nitazoxanide, Hydroxychloroquine or Ivermectin, With or Without Dutasteride, for Early Stage COVID-19: An Open-Label Prospective Observational Study in Males With Mild-to-Moderate COVID-19 (The Pre-AndroCoV Male Trial)

research Azithromycin With Nitazoxanide, Hydroxychloroquine or Ivermectin, With or Without Dutasteride, for Early Stage COVID-19: An Open-Label Prospective Observational Study in Males With Mild-to-Moderate COVID-19 (The Pre-AndroCoV Male Trial)

4 citations , October 2020 in “Research Square (Research Square)”

This study reported that more sensitive, early diagnosis and treatment of COVID-19 with drug combinations significantly improved clinical outcomes in males with or without androgenetic alopecia, preventing severe progression.

An Open-Label Prospective Observational Study of Antiandrogen and Non-Antiandrogen Early Pharmacological Approaches in Females with Mild-to-Moderate COVID-19: The Pre-AndroCoV Female Trial

research An Open-Label Prospective Observational Study of Antiandrogen and Non-Antiandrogen Early Pharmacological Approaches in Females with Mild-to-Moderate COVID-19: The Pre-AndroCoV Female Trial

6 citations , October 2020 in “medRxiv (Cold Spring Harbor Laboratory)”

This study found that early pharmacological treatment of COVID-19 in females, including those with hyperandrogenic conditions, significantly improved clinical outcomes, with spironolactone users experiencing milder symptoms and faster recovery.

research Repurposing Existing Drugs for COVID-19: An Endocrinology Perspective

34 citations , September 2020 in “BMC Endocrine Disorders”

This review highlights that while dexamethasone may reduce mortality in severe COVID-19, no other drugs have proven effectiveness for treatment, emphasizing the need for clinical trials of existing medications.

Androgen Receptor Genetic Variant Predicts COVID-19 Disease Severity: A Prospective Longitudinal Study of Hospitalized COVID-19 Male Patients

research Androgen Receptor Genetic Variant Predicts COVID-19 Disease Severity: A Prospective Longitudinal Study of Hospitalized COVID-19 Male Patients

26 citations , September 2020 in “Journal of the European Academy of Dermatology and Venereology”

This publication is a letter discussing the association between an androgen receptor genetic variant and COVID-19 disease severity in hospitalized male patients, but it reports no new research results.

Spironolactone: An Anti-Androgenic and Anti-Hypertensive Drug That May Provide Protection Against the Novel Coronavirus (SARS-CoV-2) Induced Acute Respiratory Distress Syndrome (ARDS) in COVID-19

research Spironolactone: An Anti-Androgenic and Anti-Hypertensive Drug That May Provide Protection Against the Novel Coronavirus (SARS-CoV-2) Induced Acute Respiratory Distress Syndrome (ARDS) in COVID-19

36 citations , July 2020 in “Frontiers in Medicine”

Spironolactone might help protect against severe lung problems in COVID-19 patients.

Androgenetic Alopecia in COVID-19: Comparison to Age-Matched Epidemiologic Studies and Hospital Outcomes With or Without the Gabrin Sign

research Androgenetic Alopecia in COVID-19: Comparison to Age-Matched Epidemiologic Studies and Hospital Outcomes With or Without the Gabrin Sign

32 citations , July 2020 in “Journal of The American Academy of Dermatology”

This study noted that among hospitalized COVID-19 patients, androgenetic alopecia was prevalent, and severe cases were associated with adverse outcomes such as respiratory failure, highlighting a possible link with androgen sensitivity.